REMEGEN (09995.HK) +1.750 (+3.539%) Short selling $51.58M; Ratio 7.857% announced before market open yesterday (22nd) a share placement at a 9.5% discount, aiming to raise net proceeds of HKD796 million.After surging by over 5% yesterday, REMEGEN opened 0.3% lower this morning but managed a rebound afterward. It last traded at HKD51.85, up 4.85%, marking a new two-year high, on a volume of 4.221 million shares, involving HKD215 million.REMEGEN is placing 19 million H-shares (representing about 3.37% of the enlarged share capital) at HKD42.44 per share, around a 9.51% discount to the previous day's (21st) closing price of HKD46.9. The net proceeds of around HKD796 million are intended to be used by the group to invest in R&D of its core product, Telitacicept (RC18), for the expansion of its core indications such as Myasthenia Gravis and Membranous Nephritis, and for general corporate purposes.Nomura opined in its research report that the share placement was beneficial to REMEGEN's financial position, as financial issues have long been its major burden. The broker elevated its target price for the company from HKD16.37 to HKD47.6, with a Neutral rating remaining in place.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-23 16:25.)